Company Profile

Flobio LLC
Profile last edited on: 8/8/2020      CAGE: 80JX4      UEI: YPEYKCYZB837

Business Identifier: A novel point of care blood diagnostic platform that assesses blood biology
Year Founded
2017
First Award
2019
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3401 Grays Ferry Avenue Bldg 176-1016
Philadelphia, PA 19146
   (215) 573-5702
   N/A
   www.flobiollc.com
Location: Single
Congr. District: 03
County: Philadelphia

Public Profile

FloBio is pioneering a novel point of care blood diagnostic platform that assesses blood biology and clotting status under physiologic, dynamic flow. Our proprietary microfluidic technology is designed to set a new standard for monitoring blood function in emergency critical care settings. Rapid and real-time measurements precisely identify the clotting defects, enabling clinicians to personalize management of bleeding and thrombotic risk. The results is fewer complications, improved clinical outcomes and reduced health care costs

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2023 2 NIH $1,875,604
Project Title: Point-of-care direct oral anticoagulant (DOAC) microfluidic diagnostic
2021 1 NSF $256,000
Project Title: Automated DOAC assay to determine coagulation status in emergent care
2020 1 NIH $251,628
Project Title: Point-Of-Care Device For Testing Neonate Platelet Function

Key People / Management

  Megan Jean Farrell

  Mark Kunkel

Company News

There are no news available.